Long-term follow-up study of Chinese patients with YMDD mutations: Significance of hepatitis B virus genotypes and characteristics of biochemical flares

Journal of Clinical Microbiology

Volumn 42, Issue 9, 2004, Pages 3932-3936

  Yuen, Man Fung ^a   Yuan, He Jun ^a   Sablon, Erwin ^b   Wong, Danny Ka Ho ^a   Chan, Annie On On ^a   Wong, Benjamin Chun Yu ^a   Lai, Ching Lung ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b INNOGENETICS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHINESE; CONTROLLED STUDY; DISEASE EXACERBATION; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; VIRUS MUTATION;

ADOLESCENT; ADULT; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION, MISSENSE; RECURRENCE; RNA-DIRECTED DNA POLYMERASE;

DNA VIRUSES; HEPATITIS B VIRUS;

EID: 4644235700     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.42.9.3932-3936.2004     Document Type: Article

References (24)

1. Akuta, N., F. Suzuki, M. Kobayashi, A. Tsubota, Y. Suzuki, T. Hosaka, T. Someya, M. Kobayashi, S. Saitoh, V. Arase, K. Ikeda, and H. Kumada. 2003. The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment. J. Hepatol. 38:315-321.
2. Chien, R. N., Y. F. Liaw, M. Atkins, et al. 1999. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine patients with chronic hepatitis B. Hepatology 30:770-774.
3. Dienstag, J. L., E. R. Schiff, T. L. Wright, R. P. Perrillo, H. W. Hann, Z. Goodman, L. Crowther, L. D. Condreay, M. Woessner, M. Rubin, and N. A. Brown. 1999. Lamivudine as initial treatment for chronic hepatitis B in the United States. N. Engl. J. Med. 341:1256-1263.
4. Fu, L., and Y. C. Cheng. 1998. Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC(3TC) resistance. Biochem. Pharmacol. 55:1567-1572.
5. Honkoop, P., H. G. M. Niesters, R. A. M. de Man, A. D. M. E. Osterhaus, and S. W. Schalam. 1997. Lamivudine resistance in immunocompetent chronic hepatitis B: incidence and pattern. J. Hepatol. 26:1393-1395.
6. Kao, J. H., C. J. Liu, and D. S. Chen. 2002. Hepatitis B viral genotypes and lamivudine resistance. J. Hepatol. 36:303-305.
7. Kim, J. W., H. S. Lee, G. H. Woo, J. H. Yoon, J. J. Jang, J. G. Chi, and C. Y. Kim. 2001. Fatal submassive hepatic necrosis associated with tyrosine-methionine-aspartate-aspartate-motif mutation of hepatitis B virus after long-term lamivudine therapy. Clin. Infect. Dis. 33:403-405.
8. Lai, C. L., R. N. Chien, N. W. Y. Leung, T. T. Chang, R. Guan, D. I. Tai, K. Y. Ng, P. C. Wu, J. C. Dent, J. Barber, S. L. Stephenson, and D. F. Gray. 1998. A one-year trial of lamivudine for chronic hepatitis B. N. Engl. J. Med. 339:61-68.
9. Lai, C. L., M. F. Yuen, C. K. Hui, S. G. Lestache, C. T. K. Cheng, and Y. P. Lai. 2002. Comparison of the efficacy of lamivudine and famctclovir in Asian patients with chronic hepatitis B: results of 24 weeks of therapy. 67:33-338.
10. Lau, D. T. Y., F. Khokhar, E. Doo, M. G. Ghany, D. Herion, Y. Park, D. E. Kleiner, P. Schmid, L. D. Condreay, J. Gauthier, M. C. Kuhns, T. J. Liang, and J. H. Hoofnagle. 2000. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 32:828-834.
11. Leung, N. W. Y., C. L. Lai, T. T. Chang. R. Guan, C. M. Lee, K. Y. Ng, S. G. Lim, P. C. Wu, J. C. Dent, S. Edmundson, L. D. Condreay, R. N. Chien, et al. 2001. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 33:1527-1532.
12. Liaw, Y. F., R. N. Chien, C. T. Yen, S. L. Tsai, and C. M. Chu. 1999. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 30:567-572.
13. Liaw, Y. F., N. W. Y. Leung, T. T. Chang, R. Guan, D. I. Tai, K. Y. Ng, R. N. Chien, J. Dent, L. Roman, S. Edmundson, C. L. Lai, et al. 2000. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 119:172-180.
14. Liaw, Y. F. 2001. Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. Antivir. Chem. Chemother. 12(Suppl. 1):67-71.
15. Ling, R., and T. J. Harrison. 1999. Functional analysis of mutations conferring lamivudine resistance on hepatitis B virus. J. Gen. Virol. 80(Pt. 3):601-606.
16. Lok, A. S., C. L. Lai, N. Leung, G. B. Yao, Z. Y. Cui, E. R. Schiff, J. L. Dienstag, E. J. Heathcote, N. R. Little, D. A. Griffiths, S. D. Gardner, and M. Castiglia. 2003. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125:1714-1722.
17. Melegari, M., P. P. Scaglioni, and J. R. Wands. 1998. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 27:628-633.
18. Nafa, S., S. S. Ahmed, D. Tavan, C. Pichoud, F. Berby, L. Stuyver, M. Johnson, P. Merle, H. Abidi, C. Trepo, and F. Zoulim. 2000. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 32:1078-1088.
19. Ono-Nita, S. K., N. Kato, Y. Shiratori, T. Masaki, K. H. Lan, F. J. Carrilho, and M. Omata. 1999. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: a study by in vitro full-length viral DNA transfection. Hepatology 29:939-945.
20. Yen, C. T., R. N. Chien, C. M. Chu, and Y. F. Liaw. 2000. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology 31:1318-1326.
21. Yuen, M. F., E. Sablon, C. K. Hui, H. J. Yuan, H. Decraemer, and C. L. Lai. 2001. Factors predicting hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 34(Pt. 1):785-791.
22. Yuen, M. F., T. Kato, M. Mizokami, A. O. O. Chan, J. C. H. Yuen, H. J. Yuan, D. K. H. Wong, S. M., Sum, I. O. L. Ng, S. T. Fan, and C. L. Lai. 2003. Clinical outcome and virologic profiles of severe hepatitis B exacerbation due to YMDD mutations. J. Hepatol. 39:850-855.
23. Yuen, M. F., E. Sablon, H. J. Yuan, D. K. Wong, C. K. Hui, B. C. Wong, A. O. Chan, and C. L. Lai. 2003. Significance of hepatitis B genotype in acute exacerbation, HBeAg seroconversion, cirrhosis-related complications, and hepatocellular carcinoma. Hepatology 37:562-567.
24. Zöllner, B., J. Petersen, M. Schröter, R. Laufs, S. Volker, and H. H. Feucht. 2001. 20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw. Lancet 357:934-935.